Photo Credit: Luchschenf
The Following is a summary of “improvements in moderate-to-severe hydradenitis suppurative with upadacitinib: results from a phase 2, randomized, placebo-Controlled Study,” published in the febrary 2025 ISSUE OF Dermatology by Ackerman et al.
Researchers conducted a prospective study to evaluate the effectiveness and safety of upadacitinib, selective janus kinase inhibitor, for treating hydradenitis suppurative (HS).
They ENrolled Adults with moderate-to-severe hs, who were randomized 2: 1 to receiver once-daily upadacitinib 30 mg or placebo. After 12 Weeks, placebo recipients switched to blinded upadacitinib 15 mg, while those on upadacitinib 30 mg Continued treatment though week 48. count Compred to Baseline (Hydradenitis Suppurativa Clinical Response (Hiscr50)) at Week 12.
The Results Showed That 47 Patients Received Upadacitinib and 21 Received Placebo, at Week 12, A Significant Higher Percentage of Upadacitinib Recipients Achieved Histr50 Compreded to the Historical Placebo Rate (38.3% vs 25.0%, 1-SIDED P= .018). The Adjustped Difference with the In-Trittal Placebo Group Was 14.7% (nominal P= .087) While, Histr50 Achievement with upadacitinib was consistency across Baseline Hurley Stage and Prior Tumor Necrosis Factor Inhibitor Use and Was Mintained Through Week 40. Upadacitinib’s Safety Profile Wit with predicts reports on dermatological conditions.
Investigators Concluded that the Findings Supported Further Research into the Use of Upadacitinib for the Treatment of Moderate-To-Severe HS.
